<DOC>
	<DOCNO>NCT00194987</DOCNO>
	<brief_summary>The purpose study provide medical management give treatment mother bring fetal platelet count minimize number invasive procedure fetus ( may result serious fetal injury ) .</brief_summary>
	<brief_title>A Trial Antenatal Treatment Alloimmune Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Pregnant woman eligible inclusion Very High Risk Group : PLA1 negative know platelet incompatibility fetus previous child suffer antenatal hemorrhage prior 28 week gestation ( best could estimate ) less 19 week gestation Pregnant woman eligible inclusion High Risk Group : PLA1 negative know platelet incompatibility fetus previous child suffer antenatal hemorrhage 28 week gestation ( best could estimate ) 1230 week gestation Pregnant woman eligible inclusion Standard Risk Group : PLA1 negative know platelet incompatibility fetus previous child suffer antenatal hemorrhage 2030 week gestation Women eligible inclusion Very High Risk Group : previous child suffer antenatal hemorrhage 28 week gestation great 19 week gestation Women eligible inclusion High Risk Group : previous child suffer antenatal hemorrhage prior 28 week gestation great 30 week gestation Women eligible inclusion Standard Risk Group : previous child suffer antenatal hemorrhage great 30 week gestation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alloimmune thrombocytopenia</keyword>
	<keyword>Fetal alloimmune thrombocytopenia</keyword>
</DOC>